<DOC>
	<DOCNO>NCT00452673</DOCNO>
	<brief_summary>The purpose study learn safety efficacy Dasatinib combination Capecitabine patient advance breast cancer , receive treatment taxane anthracycline</brief_summary>
	<brief_title>Phase I Study Dasatinib ( BMS-354825 ) Capecitabine Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . Female advance breast cancer previously treat taxane anthracycline No pleural pericardial effusion Not receive anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>